In vitro diagnostics company Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced on Monday that the US Food and Drug Administration granted 510(k) clearance for its Accelerate Arc system and BC kit.
This platform automates positive blood culture sample preparation for use with Bruker's MALDI Biotyper CA System and Sepsityper software.
Designed for clinical labs, the system streamlines microbial identification, bypassing the need for overnight culture methods. This reduces wait times for results, crucial in sepsis treatment. Accelerate Arc leverages Bruker's reference library for rapid identification, complementing the company's future WAVE system for antibiotic susceptibility testing.
Faster results improve patient outcomes, lower antimicrobial resistance and reduce hospital costs. Additionally, Accelerate Arc replaces overnight subculture and labour-intensive Laboratory Developed Tests, meeting regulatory pressures for FDA-cleared devices.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval